Abstract:Background Galectin-9 is a member of the family of lectin proteins and crucially regulates human immune responses, particularly because of its ability to suppress the anticancer activities of T lymphocytes and natural killer cells. Recent evidence demonstrated that galectin-9 is highly expressed in a wide range of human malignancies including the most aggressive tumors, such as high-grade glioblastomas and pancreatic ductal adenocarcinomas, as well as common malignancies such as breast, lung and colorectal cancers. However, solid tumor cells at rest are known to secrete either very low amounts of galectin-9 or, in most of the cases, do not secrete it at all. Our aims were to elucidate whether T cells can induce galectin-9 secretion in human cancer cells derived from solid malignant tumors and whether this soluble form displays higher systemic immunosuppressive activity compared with the cell surface-based protein. Methods A wide range of human cancer cell lines derived from solid tumours, keratinocytes and primary embryonic cells were employed, together with helper and cytotoxic T cell lines and human as well as mouse primary T cells. Western blot analysis, ELISA, quantitative reverse transcriptase-PCR, on-cell Western and other measurement techniques were used to conduct the study. Results were validated using in vivo mouse model. Results We discovered that T lymphocytes induce galectin-9 secretion in various types of human cancer cells derived from solid malignant tumors. This was demonstrated to occur via two differential mechanisms: first by translocation of galectin-9 onto the cell surface followed by its proteolytic shedding and second due to autophagy followed by lysosomal secretion. For both mechanisms a protein carrier/trafficker was required, since galectin-9 lacks a secretion sequence. Secreted galectin-9 pre-opsonised T cells and, following interaction with other immune checkpoint proteins, their activity was completely attenuated. As an example, we studied the cooperation of galectin-9 and V-domain Ig-containing suppressor of T cell activation (VISTA) proteins in human cancer cells. Conclusion Our results underline a crucial role of galectin-9 in anticancer immune evasion. As such, galectin-9 and regulatory pathways controlling its production should be considered as key targets for immunotherapy in a large number of cancers.

Galectin-9 Mediates the Functions of Microglia in the Hypoxic Brain Tumor Microenvironment

Abstract 2882: Characteristic immunomodulatory role of myeloid galectin-9 in the brain tumor microenvironment

Molecular and Clinical Characterization of Galectin‐9 in Glioma Through 1,027 Samples

Galectin-1 activates carbonic anhydrase IX and modulates glioma metabolism

Galectin-3 depletion tames pro-tumoural microglia and restrains cancer cells growth

Galectin-1 Induces the Production of Immune-Suppressive Cytokines in Human and Mouse T Cells

Reduced Expression of Galectin-9 Contributes to A Poor Outcome in Colon Cancer by Inhibiting Nk Cell Chemotaxis Partially Through the Rho/Rock1 Signaling Pathway

Galectin-9, a pro-survival factor inducing immunosuppression, leukemic cell transformation and expansion

Galectin-9 protein is up-regulated in astrocytes by tumor necrosis factor and promotes encephalitogenic T-cell apoptosis

T lymphocytes induce human cancer cells derived from solid malignant tumors to secrete galectin-9 which facilitates immunosuppression in cooperation with other immune checkpoint proteins

Prognostic Value and Biological Function of Galectins in Malignant Glioma.

Galectin-9/TIM-3 as a Key Regulator of Immune Response in Gliomas With Chromosome 1p/19q Codeletion

Galectin-9 Expression Clinically Associated with Mature Dendritic Cells Infiltration and T Cell Immune Response in Colorectal Cancer

Glioma-derived S100A9 polarizes M2 microglia to inhibit CD8+T lymphocytes for immunosuppression via αvβ3 integrin/AKT1/TGFβ1

High Expression Levels of SIGLEC9 Indicate Poor Outcomes of Glioma and Correlate with Immune Cell Infiltration

Galectin-9 inhibits proliferation and migration of glioma cells

Siglec-9 acts as an immune-checkpoint molecule on macrophages in glioblastoma, restricting T-cell priming and immunotherapy response

Glial TIM-3 Modulates Immune Responses in the Brain Tumor Microenvironment

Comprehensive characterization of early-programmed tumor microenvironment by tumor-associated macrophages reveals galectin-1 as an immune modulatory target in breast cancer

Galectin-9 in cancer therapy: from immune checkpoint ligand to promising therapeutic target

Glioma-Associated Sialoglycans Drive the Immune Suppressive Phenotype and Function of Myeloid Cells